First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/ refractory advanced solid tumors: Interim data

被引：0

作者：

Ahn, Eugene R.

Duvivier, Herbert Leon

Rasco, Drew W.

Rethy, Agnes

Moore, Chris

Yuet, Amy

Hankins, Sandra R.

Orlandella, Rachael

Khanna, Swati

Dekker, Joseph

Georgy, Angela

Spigel, David R.

机构：

[1] Canc Treatment Ctr Amer Chicago, Zion, IL USA

[2] Herbert Duvivier MD Prof C, Glendale, CA USA

[3] START, San Antonio, TX USA

[4] Mol Templates Inc, Jersey City, NJ USA

[5] Mol Templates Inc, Austin, TX USA

[6] Mol Templates Inc, Ste 100, Austin, TX USA

[7] Sarah Cannon Res Ins, Tennessee Oncol, Nashville, TN USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2521

引用

页数：1